Completed Glycogen Storage Disease Type II trials in France: Trial Insights

Filters: Condition: Glycogen Storage Disease Type II Status: Completed Country / region: France Clear all

17 trials match Source: ClinicalTrials.gov registrations

Trials started per year
Category	Trials
2003	3
2004	1
2005	3
2007	2
2009	1
2011	2
2013	1
2015	1
2018	1
2019	2

Trials by status
Category	Trials
Completed	17

Top lead sponsors
Category	Trials
Genzyme, a Sanofi Company	10
Amicus Therapeutics	3
Centre Hospitalier Universitaire de Nice	2
BioMarin Pharmaceutical	1
Spark Therapeutics, Inc.	1

Top conditions
Category	Trials
Glycogen Storage Disease Type II	17
Lysosomal Storage Diseases	1

Trials

Showing 1 to 17 of 17. Each trial links to its page on Pharma Observatory.

A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD) NCT04138277Phase 3CompletedAmicus TherapeuticsStarted 2019
Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease NCT03893240Not applicableCompletedSpark Therapeutics, Inc.Started 2019
A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease NCT03729362Phase 3CompletedAmicus TherapeuticsStarted 2018
Frequency of Pompe's Disease and Neuromuscular Etiologies in Patients With Restrictive Respiratory Failure Associated With Signs of Muscle Weakness NCT02746718Not applicableCompletedCentre Hospitalier Universitaire de NiceStarted 2015
Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients. NCT01898364Phase 1CompletedGenzyme, a Sanofi CompanyStarted 2013
Drug-drug Interaction Study NCT01380743Phase 2CompletedAmicus TherapeuticsStarted 2011
Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease NCT01230801Phase 1/2CompletedBioMarin PharmaceuticalStarted 2011
Pompe Prevalence Study in Patients With Muscle Weakness Without Diagnosis NCT00830583Not applicableCompletedCentre Hospitalier Universitaire de NiceStarted 2009
Late-Onset Treatment Study Extension Protocol NCT00455195Phase 4CompletedGenzyme, a Sanofi CompanyStarted 2007
Study About the Evolution of Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction and Receiving Myozyme® NCT00731081ObservationalCompletedGenzyme, a Sanofi CompanyStarted 2007
Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support NCT00268944Phase 3CompletedGenzyme, a Sanofi CompanyStarted 2005
A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease NCT00158600Phase 3CompletedGenzyme, a Sanofi CompanyStarted 2005
Extension Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602 NCT00125879Phase 2/3CompletedGenzyme, a Sanofi CompanyStarted 2005
A Prospective, Observational Study in Patients With Late-Onset Pompe Disease NCT00077662ObservationalCompletedGenzyme, a Sanofi CompanyStarted 2004
A Study of the Safety and Efficacy of rhGAA in Patients With Infantile-onset Pompe Disease NCT00059280Phase 2/3CompletedGenzyme, a Sanofi CompanyStarted 2003
Extension Study of Long-term Safety and Efficacy of Myozyme in Patients With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored Enzyme Replacement Therapy (ERT) Studies NCT00763932Phase 2CompletedGenzyme, a Sanofi CompanyStarted 2003
rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease) NCT00053573Phase 1/2CompletedGenzyme, a Sanofi CompanyStarted 2003

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory